Drug cost scrutiny and a call for greater drug price transparency are a consistent topic in the news. This pressure is coupled with a commitment from our new executive branch of government to decrease drug pricing. In response, pharmaceutical manufacturers need to ensure they have insight and a defendable narrative to describe their pricing practices which includes, how they set launch prices, their price increase patterns and how they facilitate financial access to their drugs.
Original air date: February 22, 2017
In this recorded webcast, our team of subject matter specialists discuss the following:
Please contact Melissa Cornett with any questions regarding this event.
This webcast does not offer CPE credits.
If you have any questions concerning continuing professional education (CPE), you can find answers here to frequently asked questions concerning CPE webcast participation.
© 2016 - 2017 PwC. All rights reserved. PwC refers to the US member firm or one of its subsidiaries or affiliates, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.